$71.975
Live
Insights on Intra-cellular Therapies, Inc.
Revenue is up for the last 16 quarters, 882.51K → 131.50M (in $), with an average increase of 25.1% per quarter
Netprofit is down for the last 2 quarters, -24.25M → -28.57M (in $), with an average decrease of 17.8% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 35.8% return, outperforming this stock by 15.5%
0.86%
Downside
Day's Volatility :1.94%
Upside
1.09%
36.78%
Downside
52 Weeks Volatility :46.4%
Upside
15.22%
Period | Intra-cellular Therapies, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 9.17% | 1.7% | 0.0% |
6 Months | 51.07% | 11.3% | 0.0% |
1 Year | 20.28% | 5.4% | 1.3% |
3 Years | 120.71% | 13.9% | -22.1% |
Market Capitalization | 7.7B |
Book Value | $6.14 |
Earnings Per Share (EPS) | -1.46 |
PEG Ratio | 0.0 |
Wall Street Target Price | 91.97 |
Profit Margin | -30.08% |
Operating Margin TTM | -25.81% |
Return On Assets TTM | -13.43% |
Return On Equity TTM | -22.39% |
Revenue TTM | 464.4M |
Revenue Per Share TTM | 4.84 |
Quarterly Revenue Growth YOY | 50.3% |
Gross Profit TTM | 95.2M |
EBITDA | -158.9M |
Diluted Eps TTM | -1.46 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.66 |
EPS Estimate Next Year | 1.08 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | -0.31 |
What analysts predicted
Upside of 27.78%
Sell
Neutral
Buy
Intra-cellular Therapies, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | 7.58% | 51.07% | 20.28% | 120.71% | 442.84% |
Neurocrine Biosciences Inc. | -0.91% | 28.4% | 35.75% | 40.71% | 78.24% |
Haleon Plc Spon Ads | -0.95% | 1.58% | -4.79% | 12.69% | 12.69% |
Zoetis Inc. | -10.09% | -7.81% | -12.8% | -11.14% | 48.17% |
Viatris Inc. | -2.37% | 28.76% | 25.82% | -14.76% | -29.31% |
Catalent, Inc. | -0.8% | 41.9% | 32.08% | -51.64% | 25.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | NA | NA | 0.0 | -0.66 | -0.22 | -0.13 | NA | 6.14 |
Neurocrine Biosciences Inc. | 56.72 | 56.72 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 30.04 | 30.04 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.5 | 29.5 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 225.0 | 225.0 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | Buy | $7.7B | 442.84% | NA | -30.08% |
Neurocrine Biosciences Inc. | Buy | $14.1B | 78.24% | 56.72 | 13.23% |
Haleon Plc Spon Ads | Buy | $38.4B | 12.69% | 30.04 | 9.28% |
Zoetis Inc. | Buy | $68.3B | 48.17% | 29.5 | 27.43% |
Viatris Inc. | Hold | $13.4B | -29.31% | 225.0 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 25.36% | 211.02 | -31.77% |
FMR Inc
Vanguard Group Inc
BlackRock Inc
Wasatch Advisors LP
Bellevue Group AG
venBio Select Advisor LLC
Intra-cellular Therapies, Inc.’s price-to-earnings ratio stands at None
Read Moreintra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
Organization | Intra-cellular Therapies, Inc. |
Employees | 610 |
CEO | Dr. Sharon Mates Ph.D. |
Industry | Health Technology |
Cerevel Therapeutics Holdings Inc
$71.98
-1.57%
Vaxcyte Inc
$71.98
-1.57%
Janux Therapeutics Inc
$71.98
-1.57%
Spdr Nuveen S&p High Yield Municipal Bond Etf
$71.98
-1.57%
Radnet Inc
$71.98
-1.57%
The St. Joe Co
$71.98
-1.57%
Harley-davidson, Inc.
$71.98
-1.57%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$71.98
-1.57%
Aurora Innovation Inc
$71.98
-1.57%